论文部分内容阅读
目的探究血清肌红蛋白(Myo)检验在急性心肌梗死患者中的临床价值。方法回顾性选取2015年7月至2016年7月收治的98例急性心肌梗死患者临床资料将其分为研究组,取同期健康体检正常人员50例设为对照组,两组均进行Myo检验,观察两组Myo、hs-CRP、cTnI指标水平,比较研究组不同时期血清各项指标含量。结果研究组Myo、hs-CRP、cTnI指标水平均高于对照组(P<0.05),研究组hs-CRP含量治疗后12h-1d呈上升趋势,治疗1d-3d之后逐步下降;Myo及cTnI含量治疗后12h-3d呈逐步下降趋势。结论 AMI患者采取Myo检验,能有效提高检测准确率,及早发现诊断病情,为临床治疗提供可靠依据,有助于及时治疗并提高临床效果,具临床推广和应用价值。
Objective To investigate the clinical value of serum Myoglobin (Myo) test in patients with acute myocardial infarction. Methods The clinical data of 98 patients with acute myocardial infarction admitted to our hospital from July 2015 to July 2016 were retrospectively divided into study groups. 50 normal subjects were selected as control group during the same period. Myo test was performed in both groups, The levels of Myo, hs-CRP and cTnI in the two groups were observed, and the serum levels of different indexes in the study group were compared. Results The levels of Myo, hs-CRP and cTnI in the study group were significantly higher than those in the control group (P <0.05). The hs-CRP levels in the study group increased from 12 h to 1 d after treatment and gradually decreased from 1 d to 3 d after treatment. The contents of Myo and cTnI 12h-3d after treatment showed a gradual downward trend. Conclusion The Myo test in patients with AMI can effectively improve the detection accuracy and early detection of the diagnosis of disease, provide a reliable basis for clinical treatment, and help to timely treatment and improve clinical outcomes, with clinical promotion and application value.